UA76969C2 - Lactams and their pharmaceutical use - Google Patents

Lactams and their pharmaceutical use Download PDF

Info

Publication number
UA76969C2
UA76969C2 UA2003055026A UA2003055026A UA76969C2 UA 76969 C2 UA76969 C2 UA 76969C2 UA 2003055026 A UA2003055026 A UA 2003055026A UA 2003055026 A UA2003055026 A UA 2003055026A UA 76969 C2 UA76969 C2 UA 76969C2
Authority
UA
Ukraine
Prior art keywords
substituent
group
acyl
alkyl
carbamoyl
Prior art date
Application number
UA2003055026A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of UA76969C2 publication Critical patent/UA76969C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
UA2003055026A 2000-12-01 2001-11-29 Lactams and their pharmaceutical use UA76969C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
UA76969C2 true UA76969C2 (en) 2006-10-16

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003055026A UA76969C2 (en) 2000-12-01 2001-11-29 Lactams and their pharmaceutical use

Country Status (26)

Country Link
US (3) US7153850B2 (enExample)
EP (1) EP1346993B1 (enExample)
JP (2) JP3826400B2 (enExample)
KR (1) KR100826818B1 (enExample)
CN (2) CN100577651C (enExample)
AT (1) ATE446297T1 (enExample)
AU (3) AU1850202A (enExample)
BG (1) BG107857A (enExample)
BR (1) BR0115852A (enExample)
CA (1) CA2430124C (enExample)
CZ (1) CZ20031520A3 (enExample)
DE (1) DE60140270D1 (enExample)
ES (1) ES2331299T3 (enExample)
HU (1) HUP0400806A3 (enExample)
IL (1) IL156158A0 (enExample)
MX (1) MXPA03004876A (enExample)
NO (1) NO325401B1 (enExample)
NZ (1) NZ526164A (enExample)
PL (1) PL362835A1 (enExample)
RU (1) RU2287530C2 (enExample)
SK (1) SK6582003A3 (enExample)
TW (1) TWI241302B (enExample)
UA (1) UA76969C2 (enExample)
WO (1) WO2002044180A1 (enExample)
YU (1) YU42603A (enExample)
ZA (1) ZA200304100B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100577651C (zh) * 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
WO2004069259A1 (ja) * 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
JP4711228B2 (ja) 2003-10-31 2011-06-29 味の素株式会社 複素環を有する新規縮合多環式化合物及びその医薬用途
WO2005068467A1 (ja) * 2004-01-14 2005-07-28 Ajinomoto Co., Inc. 新規縮環化合物
CN101039946B (zh) * 2004-10-13 2010-12-08 霍夫曼-拉罗奇有限公司 用作用于cdk2和血管生成的抑制剂及用于治疗乳腺、结肠、肺和前列腺癌的二取代吡唑并苯并二氮杂*类
EP1878734A4 (en) 2005-04-28 2010-02-17 Ajinomoto Kk NEW COMPOUND LACTAME
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
CN107106572B (zh) * 2014-12-22 2021-01-12 Ea制药株式会社 角膜上皮障碍治疗剂
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
WO2020151671A1 (en) * 2019-01-23 2020-07-30 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
AU8592598A (en) 1997-07-30 1999-02-22 Wyeth Tricyclic vasopressin agonists
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
CN100577651C (zh) 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
WO2004069259A1 (ja) 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤

Also Published As

Publication number Publication date
ZA200304100B (en) 2004-08-22
WO2002044180A1 (en) 2002-06-06
EP1346993A1 (en) 2003-09-24
HUP0400806A2 (hu) 2004-07-28
KR100826818B1 (ko) 2008-05-02
JPWO2002044180A1 (ja) 2004-04-02
PL362835A1 (en) 2004-11-02
CA2430124A1 (en) 2002-06-06
YU42603A (sh) 2006-03-03
AU1850202A (en) 2002-06-11
DE60140270D1 (de) 2009-12-03
HUP0400806A3 (en) 2007-11-28
AU2006241377B2 (en) 2009-01-08
NO20032439D0 (no) 2003-05-28
US7153850B2 (en) 2006-12-26
TWI241302B (en) 2005-10-11
CN1911915A (zh) 2007-02-14
EP1346993B1 (en) 2009-10-21
MXPA03004876A (es) 2004-01-27
NO20032439L (no) 2003-07-18
JP3826400B2 (ja) 2006-09-27
IL156158A0 (en) 2003-12-23
US7326701B2 (en) 2008-02-05
US20080096862A1 (en) 2008-04-24
CN1269818C (zh) 2006-08-16
EP1346993A4 (en) 2005-12-21
ES2331299T3 (es) 2009-12-29
US20060189597A1 (en) 2006-08-24
CZ20031520A3 (cs) 2003-10-15
RU2287530C2 (ru) 2006-11-20
SK6582003A3 (en) 2003-09-11
US7632830B2 (en) 2009-12-15
JP2006213732A (ja) 2006-08-17
US20040048847A1 (en) 2004-03-11
AU2006241377A1 (en) 2006-12-14
CA2430124C (en) 2011-01-11
BR0115852A (pt) 2003-12-23
NO325401B1 (no) 2008-04-21
ATE446297T1 (de) 2009-11-15
NZ526164A (en) 2004-09-24
BG107857A (bg) 2004-06-30
JP4505753B2 (ja) 2010-07-21
CN100577651C (zh) 2010-01-06
CN1487940A (zh) 2004-04-07
KR20030051893A (ko) 2003-06-25
AU2002218502B2 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
UA76969C2 (en) Lactams and their pharmaceutical use
TW215055B (enExample)
EP3517538A1 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
KR20220082092A (ko) 화합물
UA75660C2 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
EP3615019B1 (en) Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
EP3150592B1 (en) Alk kinase inhibitor, and preparation method and use thereof
UA76977C2 (en) Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
TW201028380A (en) C5aR antagonists
UA57811C2 (uk) Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
JP2025010154A (ja) 線維症及び炎症の処置のための組成物
KR20120087878A (ko) 1,3-프로판디설포닉 애시드의 수송을 위한 방법, 화합물 및 조성물
WO2012118562A1 (en) Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
ES2910049T3 (es) Moduladores heterocíclicos de la síntesis de lípidos
ES2882175T3 (es) Compuestos para su uso en el tratamiento de la hipertensión pulmonar
CN116120314A (zh) 用于调节毛发生长的组合物和方法
JPH02503794A (ja) アルツハイマー病の治療のための化合物
RU2233278C2 (ru) Пиримидиновые соединения, способ их получения и фармацевтическая композиция
HUP0202938A2 (hu) N-aril-2-(szulfonil-amino)-benzamidok mint foszfát-transzport inhibitorok és ezeket tartalmazó gyógyszerkészítmények
WO2020007322A1 (zh) 一种靶向降解bet蛋白的化合物及其应用
TW200304817A (en) Chemical compounds
TW202525293A (zh) 用於治療癌症之組合
SA95160293B1 (ar) مشتقات حمض اميني حلقي cyclic amiono acid لها نشاط تثبيط انزيم ACE وNEP
HUP0302234A2 (hu) Foszfát-transzport inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200940543A (en) Maleate, besylate and L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine